Searchable abstracts of presentations at key conferences in endocrinology

ea0010s2biog | Clinical Endocrinology Trust Historical Lecture | SFE2005

Clinical Endocrinology Trust Historical Lecture

Nieschlag E

E Nieschlag, Institute of Reproductive Medicine of the University, Muenster, Germany AbstractEberhard Nieschlag studied medicine at the Universities of Bonnand Munich and biochemistry at University College London. He went on to specialize in internal medicine and endocrinology at the University Hospitals of Mainz and Düsseldorf. He has also conducted research at the MRC Clinical Research Unit for Reproductive En...

ea0031se1.3 | (1) | SFEBES2013

Should the aging male become a father?

Nieschlag Eberhard

Couples in developed countries are increasingly delaying child bearing to later in life. While it is well known that female reproductive functions decrease and genetic risks for the offspring increase beyond the age of 35 and seize completely around the age of 50, the influence of risks of paternal age on fertility and offspring are less well known. Indeed, until recently life long fertility was assumed for the male. However, testicular function slowly declines with age and fe...

ea0025se1.1 | (1) | SFEBES2011

The metamorphosis of testosterone from a sex steroid to a universal health factor

Nieschlag Eberhard

When in the 1930s testosterone was isolated, synthesized and introduced to the clinic, it was considered predominantly a sex steroid to be used for the treatment of erectile dysfunction and hypogonadism. In the 1950s the anabolic effect was ‘discovered’ and triggered the misuse of high doses of testosterone in sports, still prevailing today. Consequently, pharmacologic research concentrated its efforts on anabolic steroids, i.e. testosterone analogues hopefully witho...

ea0010s2 | Clinical Endocrinology Trust Historical Lecture | SFE2005

The history of testosterone

Nieschlag E

2005 marks the 100th anniversary of the creation of the term hormone by Ernest Starling. Although its biological effects were known since antiquity, the name testosterone (T) was coined only in 1935, when Ernest Laqueur isolated it from bull testes. The road to this isolation was long: John Hunter had transplanted testes into capons in 1786 and Adolph Berthold postulated internal secretion from his testicular transplantation experiments in 1849. Following his obs...

ea0056s9.2 | EAA /ESE Session: Male gonadal function versus general health and vice versa | ECE2018

Klinefelter syndrome – a challenge for endocrinologists

Nieschlag Eberhard

Klinefelter syndrome (KS) is usually perceived as a disorder causing infertility and androgen deficiency and indeed, KS is the most frequent form of hypogonadism with 1 – 2 cases per 1,000 males and with a 47,XXY karyotype, the most frequent male chromosome disorder. Yet the incidence of the syndrome is probably significantly higher than the diagnosed casas suggest. Although subtle symptoms may be already evident in childhood and puberty, androgen deficiency usually only ...

ea0014p469 | (1) | ECE2007

Long-term experience and pharmacogenetic aspects of safety in 101 treatment-years with a long-acting formulation of testosterone undecanoate in substitution therapy of 66 hypogonadal men

Zitzmann Michael , Nieschlag Eberhard

Objective: A reliable form of androgen substitution therapy in terms of favorable kinetics and tolerance as well as effective restoration of androgenicity is paramount in hypogonadal men. A new feasible modality is the intramuscular injection of the long-acting ester testosterone undecanoate (TU).Design: Analysis of safety data accumulated during 101 treatment-years in 66 hypogonadal men receiving altogether 510 injections of 1000 mg TU in 10–14-we...

ea0020p290 | Clinical case reports and clinical reports | ECE2009

Intramuscular testosterone undecanoate – the experience of 11 years

Zitzmann Michael , Saad Farid , Nieschlag Eberhard

A reliable form of androgen substitution therapy in terms of favorable kinetics and tolerance as well as effective restoration of androgenicity is paramount in hypogonadal men. A feasible modality is the intramuscular injection of the long-acting ester testosterone undecanoate (TU).We report data from 183 patients (99 with primary, 70 with secondary hypogonadism and 14 with late-onset hypogonadism) aged 15–70 years (mean 37±12 years) receiving ...

ea0011p177 | Clinical practise and governance | ECE2006

Symptom-specific thresholds for testosterone deficiency modulate complaints and metabolic risk in 434 aging male patients

Zitzmann M , Faber S , Nieschlag E

Objective: The structure of psychological and somatic complaints of aging male patients in relation to sex hormone patterns and metabolism has not been fully elucidated, especially in regard to late-onset hypogonadism.Methods: We investigated the nature of complaints in 434 consecutive patients aged 50–86 years attending our andrology unit and their association with physical characteristics, life style habits and sex hormone levels.<p class="abs...

ea0011p178 | Clinical practise and governance | ECE2006

Longterm experience of more than 8 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal men

Zitzmann M , Saad F , Nieschlag E

Objective: A reliable form of androgen substitution therapy in terms of favorable kinetics and tolerance as well as effective restoration of androgenicity is paramount in hypogonadal men. A feasible modality is the intramuscular injection of the long-acting ester testosterone undecanoate (TU).Design: We report data from 22 patients (15 with primary and 7 with secondary hypogonadism) aged 30 to 65 years (mean 43.8±8 years) who received injections of ...

ea0008s17 | Consequences of a lack of androgens | SFE2004

ANDROGEN ACTION AND THE MALE ADULT PHENOTYPE FROM YOUTH TO SENESCENCE

Nieschlag E , Gromoll J , Zitzmann M

Testosterone is the hormone that turns males into men and a lack of testosterone, whether of primary or secondary origin, causes hypogonadism characterized by lack of pubertal development or loss of maleness. It was generally assumed that in a man with a normal androgen receptor (AR) androgenicity is regulated by testosterone serum concentrations, slightly modified by SHBG. Only recently it became evident that variations in the AR gene influence testosterone action. Modulation...